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Need for an incentive-based reimbursement policy toward
quality care for dialysis patient management
HIDEO HIDAI
Yokohama Dai-ichi Hospital, Yokohama, Kanagawa, Japan
Need for an incentive-based reimbursement policy toward sources for end-stage renal disease (ESRD) treatment
quality care for dialysis patient management. has been a major concern for the medical professionals
Background. In view of the growing dialysis population and and policy makers [1, 2].the increasing reimbursement cost in the industrialized coun-
Although dialysis in Japan is known to have thetries, a critical evaluation of the dialysis economy is warranted.
world’s highest prevalence rate (1473 per million, 1998)Methods. Data for the reimbursement and dialysis patients’
statistics were collected from the National Medical Care Ex- and the lowest crude one-year death rate (9.2%, 1998)
penditure (NMCE), 1979–1996, which was published by the [3], little is known about its socioeconomic status and
Japanese government, and the article “An overview of regular reimbursement policy.dialysis treatment in Japan,” 1979–1998, by the Japanese Soci-
Here, the statistical data on the dialysis-related reim-ety for Dialysis Therapy, as well as unpublished data from the
bursement and evaluations of cost and cost-effectivenessYokohama Dai-ichi Hospital and 10 affiliated urban dialysis
centers. of dialysis in Japan are presented.
Results. From 1979 to 1996, the dialysis population increased
5.2 times and the NMCE increased 2.5 times, whereas the end-
stage renal disease (ESRD) payment increased only 1.8 times. METHODS
Because of a drastic reduction in the dialyzer cost and the
Statistical data for dialysis in Japandialysis-related technical fee, both the percentage of ESRD-
related payment within NMCE and ESRD payment per capita Hospital reimbursement and statistical data relating
per year decreased from 5.4 to 4.1% and from 16.3 million to dialysis in Japan were collected from several publishedyen to 5.6 million yen, respectively. Despite this drastic cost
articles. They include the National Medical Care Expen-reduction, the patient survival and quality of life determined
diture (NMCE) annual report 1979–1996 [4], the Reportby the social rehabilitation rate did not decline.
Conclusion. The Japanese health insurance policy for dialysis on the Survey of Medical Care Activities in Public Health
management achieved a successful cost cut during the 1979–1996 Insurance (SMCA-PHI) annual report 1996 [5], and the
period by using an incentive-based payment system toward Revised Point Fee System for Social Insurance 1967–quality care. However, the forthcoming further exponential
1998 [6]—all of which were published by the Ministryincrease in the dialysis population may put the dialysis economy
of Health and Welfare—as well an article entitled, “Anand hence dialysis care quality in jeopardy. Effort must be
made to reduce the ESRD-related cost through prevention Overview of Regular Dialysis Treatment in Japan,”
of the progression of kidney diseases, propagation of renal which was published annually during the period of 1973–
transplantation, and internationalization of continuous ambu-
1998 by the Japanese Society for Dialysis Therapy (JSDTlatory peritoneal dialysis and erythropoietin cost. A reduction
report) [3, 7]. Data were also obtained from the claimsin dialysis reimbursement, if necessary, must be achieved
through an incentive-based system toward quality patient care. and the statistics from 833 dialysis patients treated at
the Yokohama Dai-ichi Hospital and 10 urban satellite
clinics in the Kanagawa district (YDH; unpublished data).
Developed countries are facing the problem of a rap- Also quoted for international comparison are excerpts
idly growing dialysis population and hence increasing of the United States Renal Data System Annual Data
dialysis-related cost. Justifiable allocation of medical re- Reports (USRDS) in 1995, 1996, 1998, and 1999 [8–18],
and data from the 1993 Nephrology News and Issues [19].
Key words: Japanese dialysis, hospital reimbursement, dialysis cost,
ESRD expenditure in JapanCAPD, erythropoietin.
The NMCE, the only statistics that cover all healthReceived for publication September 23, 1999
insurance expenditures and payments by patients in Ja-and in revised form January 6, 2000
Accepted for publication February 1, 2000 pan, has reported ESRD expenditure data since 1979.
ESRD expenditures were listed as the expenditures forÓ 2000 by the International Society of Nephrology
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Table 2. Standard hemodialysis prescription and outcomeTable 1. Dialysis patient characteristics
YDH JPN USA JPN USA
prescribed delivered
Age (average) 58.3 59.9 56.0 dose dose
Primary disorder %
CGN 39.3 52.5 17.2 Qb mL/min 190 361
Length of dialysis session minutes 241 197DM-N 16.3 24.0 33.2
NS 8.5 4.4 24.0 Dialyzer surface area m2 1.49 1.32
Kt/V 1.33 1.18,1.32Dialysis modality %
Center HD 99.2 94.6 84.9 Dialyzer reuse % 0 71
Hospital admissions per year 0.59 1.41Home HD 0 0.04 0.9
CAPD 0.8 4.4 9.1 One-year crude death rate % 9.2 23.3
Blood access graft % 3.7 4.8 63.5 Abbreviations are: JPN, JSDT report, 1995–98; USA, USRDS report, 1995–
Use of EPO % 59.0 78.0 83.5 ’96, ’98 and ’99.
Abbreviations are: YDH, Yokohama Dai-ichi Hospital and 10 affiliated clinics
(833 patients) are urban type dialysis chain in the Kanagawa district; JPN, Japa-
nese Society for Dialysis Therapy (JSDT) report 1998; USA, USRDS report
1996, 1998 and 1999; CGN, chronic glomerulonephritis; DM-N, diabetic nephrop-
athy; NS, nephrosclerosis. phropathy (DM-N), on the medical care reimbursement
[10]. Together with the tendencies of aging population
and growing diabetic population among Japanese dial-
ysis patients, the influence of these factors on the YDH“nephritis, nephrosis and renal failure” that were defined
claims are examined (Mann–Whitney U-test).according to the classification of the ICD, version 9 [20].
In addition to the dialysis cost, therefore, these expendi- Japan has the highest prevalence rate of
tures include the cost for nephrology-related disorders, dialysis population
such as glomerulonephritis, acute renal failure, conserva-
Japan is known to have the world highest prevalencetive ESRD treatment, and although small, the fee for
rate of dialysis [17]. The reason for this high prevalencerenal transplantation.
rate is not entirely known. In the past, some incidencesThe SMCA-PHI annual report consists of the claims
of “needless” dialysis or dialysis performed “too early”to the government-managed insurance and the national
were speculated [24, 25]. In order to assess whetherhealth insurance, which collectively cover 65.2% of the
“needless” or “too early” dialysis are in practice in JapanJapanese population. However, the SMCA-PHI annual
at an unusually high rate, YDH patients who were initi-report does not include the patients’ out-of-pocket pay-
ated hemodialysis at the Yokohama Dai-ichi Hospitalment. It lacks the exact number of the patients on dial-
after 1995 were examined for their predialysis serumysis, and it is limited to the claims in June [5]. According
creatinine levels at the first dialysis and for the presenceto the SMCA-PHI data from June 1996, which differenti-
or absence of uremic symptoms at that time.ate the “renal failure” expenditure [5,328,321 155 points
($444,026,763) 1 point 5 ¥10] from the “nephritis,
nephrosis and renal failure” expenditures combined RESULTS
[5,921,116 580 points ($493,426,382)], 90% of the “ne-
Characteristics, hemodialysis prescription, and thephritis, nephrosis and renal failure” expenditure (al-
outcome of Japanese patientsthough these nomenclatures were changed to “glomeru-
The summary for standard hemodialysis patient char-lar disease, tubulointersititial disease and renal failure”
acteristics, hemodialysis prescription, and outcome insince 1995 according to ICD version 10) [21] is attributed
Japan [3, 7] and the United States [8, 9, 11–15] are pre-to the “renal failure” expenditure.
sented in Tables 1 and 2.In Japan, renal transplantation contributes little to
As shown in Table 1, Japanese patients have fewerthe renal failure treatment, and in 1998, only 658 renal
incidences of diabetes as the primary disorder and prefertransplantations were performed (including 149 cadaver
outpatient (non-home) hemodialysis and subcutaneoussources) [22]. Based on the average expenses for the
arteriovenous fistula as the blood access. Japanese dial-living-related and cadaveric transplantation [23], the re-
ysis patients are given less erythropoietin (EPO) thannal transplantation cost is estimated to contribute to less
patients in the United States because of the specific in-than 1.0% of the renal failure expenditure in Japan.
structions given by the Ministry of Health and Welfare,Although constantly overestimated by 10%, the “glo-
namely, that their hematocrit values must not exceedmerular disease, tubulointerstitial disease and renal fail-
30%. Because of the notoriously strict policy set by theure” expenditure in the NMCE data are regarded as
local health insurance payer’s judge of the Kanagawathe representative reimbursement for ESRD in Japan
district, the use of EPO is even more restricted for thethroughout these discussions.
YDH group. Japanese hemodialysis practice has theUSRDS reports have shown the impact of aging and
primary kidney diseases, especially that of diabetic ne- characteristics of milder and longer dialysis sessions with
Hidai: Dialysis reimbursement policy 365
Table 3. Standard hospital reimbursement for outpatient ESRD payment showed only a mild increase, and as a
hemodialysis (HD) in Japan
consequence, the percentage of the ESRD payment over
Japanese U.S. NMCE declined during these 17 years (Fig. 1).
yen dollarsb As shown in Figure 2, during the 5.2 time increase in
Comprehensive fee (4 hours dialysis), dialysis population, the ESRD payment per patient had
including dialysis solution, anticoagu-
a drastic decrease to a level that is only 35% of 1979,lant, and labor cost (Dr., Ns., CE, etc.) ¥21.100/HD $175.8/HD
Medical management fee for outpatient which is mainly a result of the reduction in the dialyzer
dialysis, including routine lab exam, cost and the dialysis-related technical fee. As a conse-routine chest x-ray, routine EKG ¥29.000/mo $241.7/mo
quence, the ESRD payment versus NMCE decreasedDialyzer cost ,1.5 m2, high flux ¥4.020/HD $33.5/HD
EPO 1.500 U 3 3/weeks ¥46.215/mo $385.1/mo from 5.4 to 4.1% (Table 5).
Medication other than EPOa ¥22,471/mo $187.3/mo Despite the previously mentioned drastic decrease inOther including revisiting fee and
the ESRD payment per patient, as shown in Figure 3,hospital lunch ¥17,810/mo $67.9/mo
Grand total ¥442,056/mo $3,683.4/mo the one-year crude death rate, five-year survival rate,
a Estimated from SMCA-PHI data (June 1996) and social rehabilitation rate under age 60 (including
b $1 5 ¥120 rate students, part-time workers, and housewives) showed no
deterioration during the 1973 to 1989 period [7].
Of note, a slightly unfavorable tendency has been seen
in the one-year crude death rate and five-year survivalhigher Kt/V values than those in the Unites States. The
rate since 1989.dialyzer is not reused in Japan.
As for outcome, Japanese patients have a lower inci-
Aging of the Japanese dialysis populationdence of hospital admission-required problems and a
The Japanese population is known to have aged verylower one-year crude death rate than patients in the
rapidly during the latter half of the 20th century [26], andUnited States (Table 2).
even faster aging is occurring among the dialysis popula-The standard reimbursement costs for outpatient cen-
tion, as shown in Figure 4. JSDT reports revealed thatter hemodialysis were calculated from the Revised Point
the average age of the incidence and the prevalence ofFee System for Social Insurance 1998, and SMCA-PHI
dialysis patients were 50.0 and 46.2 years, respectively, indata are shown in Table 3 [5, 6].
1981, and 62.7 and 59.9 years, respectively, in 1998 [3, 7].
The Japanese point fee system for reimbursement No influence of aging, except for the age ,19-year-old
group, was noted on the dialysis cost in the YDH claimsThe Japanese point fee system for hemodialysis has
[¥298,390 per month ($2486 per month) for the ,19-year-given an incentive toward longer dialysis session since
old age group; ¥461,532 per month ($3486 per month)1978, larger dialyzer since 1981, and better efficiency
for the 20 to 44-year-old group; ¥479,378 per monthdialyzer (sieving coefficient for b2 microglobulin .0.4)
($3,955 per month) for the 45 to 64-year-old group;since 1996. Also, a short-term incentive has been given
¥454,940 per month ($3,791 per month) for the 65 to 74-to non-ETO sterilization, to reverse osmosis water puri-
year-old group; ¥449,146 per month ($3,743 per month)fication, and to stable ultrafiltration. At present, the same
for the age .75-year-old group; and ¥468,644 per monthincentive payment is included in the comprehensive fee.
($3,905 per month) on the average].For example, the use of a dialyzer with better efficiency
is paid 64 to 66 points ($5.3 to $5.5) more than of conven-
Increasing DM-N patientstional ones, and a dialysis session of four hours or more
As in other industrialized countries [27], Japan’s popu-is paid 480 points ($40) more than that of a treatment
lation of DM-N patients is increasing. JSDT reports haveless than four hours (1 point 5 ¥10; Table 4) [6]. Extra
shown that both the percentage of incidence and thepayments for night dialysis, holiday fee, and initiation
prevalence of DM-N patients rose from 11.0 and 5.2%,period fee are not included in Table 4.
respectively, in 1981 to 35.7 and 24.0%, respectively, in
ESRD payment and NMCE 1998. In contrast, the incidence and the prevalence of
chronic glomerulonephritis decreased from 61.5 andIn 1979, 525.7 billion yen ($2.5 billion) or 5.4% of
75.7%, respectively, in 1981 to 35.0 and 52.5%, respec-the NMCE was spent toward the total ESRD payment.
tively, in 1998. (Fig. 5) [3, 7].Despite the exponential increase in dialysis population
The claim for DM-N patients [¥481,106 per monthduring the subsequent 17 years, in 1996, only 4.1% [938.6
($4,009 per month)] was slightly higher than that of otherbillion yen ($8.6 billion) out of 23.0 trillion yen ($210.8
disorders [¥475,032 per month ($3,959 per month) forbillion) for NMCE] was spent toward the ESRD pay-
chronic glomerulonephritis, ¥450,015 per month ($3,750ment (Table 5).
In contrast to the steep linear increase in NMCE, the per month) for nephrosclerosis, and ¥468,644 per month
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Table 4. Major change in incentive-giving Point Fee System
Fee for
ì
í
î
dialysis solution
saline
anti-coagulantYear Outpatient technical fee Dialyzer cost (HFK only)
Including dialyzer cost1978 Claims as needed
ì
ï
þ
ü
ï
î
3,100p 5 h . session
($148)
4,000p 5 h % session , 9 h
($190)
4,100p 9 h % session
($195)
$1 5 ¥210
1981 $1 5 ¥221 Claims as needed
ì
ï
þ
ü
ï
î
1,300p 5 h . session
($59)
2,000p 5 h % session , 9 h
($90)
2,100p 9 h % session
($95)
ì
ï
þ
ü
ï
î
900p , 1.5 m2
($41)
1.5 m2 % 930p , 2.0 m2
($42)
2.0 m2 % 960p
($43)c
1988 $1 5 ¥128 Claims as neededa
ì
þ
ü
î
1,250p 4 h . session
($98)
1,700p 4 h % session
($133)
ì
ï
þ
ü
ï
î
700p , 1.5 m2
($55)
1.5 m2 % 740p , 2.0 m2
($58)
2.0 m2 % 760p
($59)c
MMF-1 Included in the1994 comprehensive fee
ì
þ
ü
î
1,600p 4 h . session
($157)
2,100p 4 h % session
($206)
ì
þ
ü
î
505p , 1.5 m2
($50)
1.5 m2 % 525p
($51)c
comprehensive feeb$1 5 ¥102
MMF-1 Included in the1996 comprehensive fee
ì
ï
þ
ü
ï
î
1,600p 4 h . session
($147)
2,080p 4 h % session
($191)
2,100p 5 h % session
($193)
ì
ï
ï
þ
ü
ï
ï
î
group I 435p , 1.5 m2
($40)
1.5 m2 % 455p
($42)
group II 455p, 1.5 m2
($42)
1.5 m2 % 475p
($44)c
comprehensive feeb$1 5 ¥109
MMF-2
1998 comprehensive fee
ì
ï
þ
ü
ï
î
1,630p 4 h . session
($136)
2,110p 4 h % session , 5 h
($176)
2,210p 5 h % session
($184)
ì
ï
ï
þ
ü
ï
ï
î
group I 326p , 1.5 m2
($27)
1.5 m2 % 354p
($30)
group II 402p , 1.5 m2
($34)
1.5 m2 % 418p
($35)
$1 5 ¥120
Abbreviations are: p, point (1 point 5 ¥10); HFK, hollow fiber kidney; MMF-1, medical management fee for outpatient; 2,500 points/mo ($208/mo); MMF-2,
medical management fee for outpatient; 2,900 points/mo ($242/mo); ’98 comprehensive fee, includes fee for routine laboratory examinations, chest x-ray and EKG.
Group I used a standard dialyzer, UFR .3.0 mL/mm Hg/hour, and group II used a high flux dialyzer, UFR .5.0 mL/mm Hg/hour and sieving coefficiency for
b2-microglobulin .0.4.
a RO fee; 30 points (’88–92; $2.5)
b UFR controller fee; 30 points (’94–’97; $2.5)
c Non-ETO sterilized dialyzer fee; 30,15 points (’81–’96) ($2.5,$1.3)
($3,905 per month) for the average], although not sig- must be made on the influence of the individual patient’s
unique features, especially those of DM-N patients, thenificantly (P 5 0.17).
YDH patients had 3.0 to 3.7 mg/dL higher initial serum
Serum creatinine levels and associated symptoms at creatinine levels than those of the USRDS patients [18]
the initiation of dialysis for all age groups. As shown in Table 1, the prevalence
rate of DM-N among the dialysis population differsDialysis was initiated on 179 patients at the Yokohama
Dai-ichi Hospital after 1995, and their mean serum creat- markedly in the United States versus Japan. The influ-
ence of DM-N on the initial serum creatinine levels ofinine level was 11.9 mg/dL with a wide distribution from
5.0 mg/dL in a 64-year-old DM-N patient under respira- the YDH patients (56.9 years on the average) is shown
in Figure 6, where the average initial creatinine value oftory distress to 31.2 mg/dL in a 45-year-old chronic glo-
merulonephritis patient with uremic symptoms. 10.0 mg/dL exceeds that of the USRDS cases except for
the age 20 to 44-year-old group.As shown in Figure 6, their initial serum creatinine
levels were as such that the serum creatinine level had a Of the 179 YDH patients, only 9 patients (5%) were
asymptomatic at the onset of dialysis, and 95% had eitherreciprocal relationship with age. Although consideration
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Table 5. Change in NMCE, ESRD payment and dialysis population
ESRD
ESRD payment/NMCE payment
ESRD payment/ Dialysis dialysis patient/year
Year NMCE % population ¥ thousand¥ billion
1979 9,074.3 525.7 5.4 32,331 16,259.9
1980 10,534.9 572.5 5.4 36,397 15,729.3
1981 11,252.3 496.0 4.4 42,223 11,747.2
1982 12,105.3 539.1 4.5 47,978 11,236.4
1983 12,699.0 450.1 3.5 53,017 8,489.7
1984 13,192.7 571.3 4.3 59,811 9,551.8
1985 14,028.7 543.2 3.9 66,310 8,191.8
1986 14,920.9 469.1 3.1 73,537 6,379.1
1987 15,816.3 553.0 3.5 80,553 6,865.0
1988 16,399.6 590.3 3.6 88,534 6,667.5
1989 17,249.7 565.6 3.3 83,221 6,796.4
1990 17,976.4 668.8 3.7 103,296 6,474.5
1991 18,995.1 807.3 4.3 110,303 6,941.3
1992 20,316.6 705.4 3.5 123,926 5,692.1
1993 20,975.7 838.9 4.0 134,298 6,246.5
1994 21,576.5 845.2 3.9 143,709 5,881.3
1995 21,863.3 929.3 4.2 154,413 6,018.2
1996 22,979.0 938.6 4.1 167,192 5,613.9
Abbreviations are: NMCE, National Medical Care Expenditure; ESRD, end-stage renal disease.
Fig. 1. Annual change of NMCE and ESRD
payment. The National Medical Care Expen-
diture (NMCE) increased linearly from 9074.3
billion yen ($43.2 billion) in 1979 up to 22,979
billion yen ($191.5 billion) in 1996 (2.53 times
in yen), whereas the end-stage renal disease
(ESRD) payment increase was modest [525.7
billion yen ($2.5 billion) in 1979 to 938.6 billion
yen ($7.8 billion) in 1996 (1.79 times in yen)].
Symbols are: (d) NMCE in trillion yen; (j)
ESRD payment in billion yen; (n) ESRD pay-
ment/NMCE in percent.
uremic or congestive heart failure symptoms such as The Japanese health care system, consisting primarily
of the Social Health Insurance Organization and theanorexia, nausea, vomiting, lethargy, bleeding tendency,
palpitation, and/or dyspnea. Most of the nine patients who Governmental Health Insurance Organization, covers
100% of their population.started dialysis without any symptoms sought early initia-
tion in order to achieve a prompt social rehabilitation. As for the quality outcome of the national health care
system in general, the Japanese system achieves the low-
est premature mortality and stillbirth rates among devel-
DISCUSSION
oped countries. Japanese life expectancy at birth is the
The Japanese health care system and the point longest, despite that the gross national product spending
fee system on health care is 7.3%, which is the lowest among the
countries that carry a Bismarck-type of health care sys-As for funding resources, the Japanese health care
system belongs to the Bismarck model, as those in Ger- tem [28].
In Japan, care providers are consisting of both publicmany and France.
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Fig. 2. Annual change of dialysis population
and ESRD payments. Despite a 5.2 times in-
crease in dialysis population from 1979 to 1996,
ESRD payment had a drastic decrease from
¥16,259,900 per capita per year to ¥5,613,900
per capita per year ($77,428 per capita per year
to $46,283 per capita per year). As a result,
ESRD payment per NMCE declined from 5.4
to 4.1%. Symbols are: (h) dialysis population;
(m) ESRD payment/dialysis patient/year; (n)
percent ESRD payment/NMCE.
Fig. 3. Annual change in the one-year crude
death rate (d), five-year survival rate (r), so-
cial rehabilitation rate (s), and ESRD pay-
ment per patient (m). During the 1979–89 pe-
riod, when ESRD payment per patient was
reduced to 35%, one-year crude death, five-
year survival, and social rehabilitation rates
were not worsened. The social rehabilitation
was defined as for those aged ,60 years and
included students, part-time workers, and
housewives.
and private organizations, and in the field of dialysis, Although the technical fee, the medical management
fee and the comprehensive fee are defined by the point72.4% (2235 out of 3085) belong to the private organiza-
tions, which provide their service to 77.7% (144,804 out fee system, neither doctors, clinical engineers (CEs), nor
nurses are given these payments. All of the point feesof 186,251) of all Japanese dialysis patients [3].
As for reimbursement, a fee-for-service system is become the income of the care providers, while the care
providers pay salaries to the medical staff, including doc-adopted in which a fixed fee, counted from the number
of points (1 point 5 ¥10) for each item of services, is tors, on fixed wage bases [28].
paid toward the monthly bill from the care providers.
Features of Japanese dialysisThese billed points are subjected to review at two levels:
first by the allied offices of the Social and National Health In Japan, the quality of dialysis provided to patients
is uniform. All dialysis patients are covered by eitherInsurance Unions in each prefecture and second by the
patient’s own health insurance offices. Through this two- social insurance or welfare aid so that even an extremely
affluent patient does not have to pay more than ¥10,000review process, some of the billed points are declined.
For example, high points from EPO are declined if the ($83.3) per month. As shown in Table 2, dialyzers are
never reused except for experimental purposes, althoughhematocrit value of the patient exceeds over 30%.
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Fig. 4. Aging of Japanese dialysis patients.
The speed of aging of the dialysis population
in Japan is markedly faster than that of the
general Japanese population. Symbols are:
(r) incident patients; (j) prevalent patients;
(m) general population.
Fig. 5. Annual change of incidence and prev-
alence rate for chronic glomerulonephritis
(CGN) and diabetic nephropathy (DM-N). As
in other developed countries, the prevalence
and the incidence of DM-N patients are in-
creasing yearly, and finally in 1998, the inci-
dence of DM-N patients (35.7%) surpassed
that of chronic glomerulonephritis (35.0%).
Symbols are: (h) incident CGN patients; ( )
prevalent CGN patients; ( ) incident DM-N
patients; (j) prevalent DM-N patients.
their law does not preclude reuse. Patients prefer outpa- 1970s [30], the dialysis population increased exponentially
(y 5 1.7743 3 102X2 2 2.3208 3 104X 1 7.5644 3 105;tient center hemodialysis due not only to their “white
coat”-dependent behavior, but also to the relatively easy r 5 0.9742) [31].
However, because of the subsequent drastic reductionaccess to their hemodialysis centers (71.5% of the pa-
tients can commute to their center within 30 min) [29]. in cost payment per patient, the overall ESRD expendi-
tures achieved a modest increase, and the ESRD expen-Under these socioeconomic circumstances, together
with the incentive created by the high dialysis fee in the diture/NMCE, instead, had a tendency to decrease.
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Fig. 6. Average serum creatinine level at ini-
tiation of dialysis. From January 1995 until
June 1999, 179 patients initiated dialysis at the
Yokahama Dai-ichi Hospital and 10 urban sat-
ellite clinics in the Kanagawa district (YDH),
and their serum creatinine levels before their
first dialysis session are shown here. In com-
parison with the USRDS patients who initi-
ated dialysis between 1995 and 1997, the YDH
patients had 3.0 to 3.7 mg/dL higher initial
serum creatinine levels for every age group
than that of the USRDS patients. Symbols are:
( ) USRDS 1995–1997; (h) YDH 1995–1999;
(j) YDH-DM 1995–1999.
Success of Japanese dialysis in the field of causes for the high prevalence rate for dialysis may be
the uniformity in the quality of dialysis, with no or verymedical economy
little out-of-pocket payment by the patient, and the con-Since no decline was noted in the survival or social
venient access to a dialysis center. A high referral raterehabilitation rate during this period, the Japanese dial-
of ESRD patients to dialysis facilities by general prac-ysis system can be regarded as having attained a success
titioners, who have no “exclusion policy,” may be an-even in the area of medical economy [31]. This success
other contributing factor.is attributed, at least part, to the incentives for higher
The USRDS reports revealed that a significantlypay given toward the dialysis with better quality, in that
higher cost was paid for the aged or diabetic patientsthe session length affects payment scale (Table 4).
than others [10]. The YDH claims observed the sameHowever, the further exponential increase in dialysis
tendency for diabetics, although this was without statisti-population, especially those in aged or diabetic patients,
cal significance.may jeopardize both medical economy and dialysis qual-
ity. The reason for Japan’s highest prevalence rate of Prevention of catastrophic increase in the
dialysis population, in addition to its very low renal trans- dialysis expenditure
plantation rate, and its high survival rate on dialysis (repre- To avoid a further catastrophic increase in the dialysis
sented by a 49-year-old male in Niigata prefecture who expenditure, every effort should be made to prevent
has dialysis history for 32 years at December 1998) must progression of kidney diseases, including DM-N, for
be investigated not only for the medical and socioeco- propagating renal transplantation, and for international-
nomic factors, but also for cultural and religious factors. ization of the medication cost and continuous ambula-
tory peritoneal dialysis (CAPD) cost.Initiation of dialysis “too early”?
Among developed countries, Japan has the lowest re-
Since the YDH patients were shown to have high nal transplantation rate in ESRD patients [17]. Although
initiation serum creatinine levels and associated initia- the Organ Transplantation Act passed the Japanese Diet
tion symptoms, the so-called “needless” or “too early” in 1997 [33], renal transplantation from heart-beating
initiation of dialysis are unlikely reasons for the high cadavers is yet to be fully approved by the Japanese
dialysis prevalence rate, at least in the Kanagawa district. society. The Japanese Ministry of Health and Welfare
Although no nationwide data are currently available, at should allocate more funds and make more effort toward
the time of debating the “too early” dialysis theory, the propagation of renal transplantation, as renal trans-
1989 JSDT data showed an average initial serum creati- plantation may improve the quality of life of ESRD
nine level of 12.8 mg/dL for the age 20 to 44 group, 10.7 patients [34] and may keep the reimbursement at a level
mg/dL for the age 45 to 64 group, 9.5 mg/dL for the age below half of that of dialysis [16, 35].
65 to 74 group, 8.7 mg/dL for the age .75 group, and
Internationalization of the EPO and CAPD cost9.0 mg/dL for DM-N, which are 1.0 to 1.7 mg/dL lower
than those of YDH, but 1.7 to 2.0 mg/dL higher than The pharmaceutical expenditure per patient in Japan
is known to be prominent among developed countriesthose of the USRDS data [24, 25]. The most significant
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[36]. The high price tag for drugs, such as EPO and low are almost equal to those of registered nurses. The Clini-
molecular weight heparin, when compared with that in cal Engineer Act prohibits dialyzer handling, including
other countries is considered to be one of the major reprocessing dialyzers, by nonlicensed personnel.
contributing factors [37]. For example, the cost of EPO Considering the expensive labor cost for reprocessing
is $47.7 for 1500 units in Japan, whereas the cost is $15 dialyzers and the cost for reprocessing machines with
to U.S. Medicare in 1995 (assuming EPO cost in USA expensive charges for the extra rooms, the author does
was proportional to the units contained and assuming not think that reusing dialyzers is a cost savings in Japan.
$1 was equivalent to ¥100) [6]. If Japan’s EPO price Apart from the economy, reuse of the dialyzer may
were the same as that for U.S. Medicare, 7.5% of the become an inevitable practice in the future because of
Japanese ESRD payment could have been saved during the need for reducing pollution by waste products, in-
the period of 1990 to 1998 [32]. cluding dialyzers and other disposables.
Although the price for 1500 units of EPO in Japan
Medicare policy and outcomedecreased to $29.6 in 1998 ($1 5 ¥120), Japan’s EPO
price is still about twice that in the United States. The U.S. Medicare policy in the past was directed
The cost of CAPD is less than that of hemodialysis in toward curtailing the direct cost for dialysis; this was to
all countries in the world except in Japan [17, 38], and restrain and fix the composite rate per one dialysis ses-
hence, several countries maintain a policy to promote sion to approximately $140 ($21,840 per year), regardless
CAPD. In contrast to other countries, since 1988, the of the inflation rate [44].
reimbursement for CAPD in Japan has been set higher This Medicare policy forced care providers to slash
than hemodialysis because of a foreign political pressure. their costs by reducing the number of registered nurses,
For example, hemodialysis payments versus CAPD pay- using small, reused dialyzers, and shortening the dialysis
ments per patient per year in Japan [39], the United sessions for the purpose of multiple shifts per day, which
States [16], and France [40] are $44,121 versus $56,781, improves the efficiency of investment on the dialysis
$50,000 versus $44,000, and $80,000 versus $42,000, re- equipment.
spectively. Internationalization of the CAPD cost is As a result of this “cheap” dialysis practice pattern,
needed, too. complications occurred frequently, necessitating multi-
ple hospital admissions of dialysis patients [45–48]. Be-Dialyzer reuse cannot be practical in Japan
cause of the resulting expensive average admission fee
Dialyzer reuse is a widely accepted practice in the of $20,000 per year, the Medicare payment ($51,174) and
world mostly because of economic reasons, although
the extra Medicare payment totaled as high as $55,763
controversy still exists with regard to the influence on
in 1993 [19]. This number exceeds the average Japanesethe morbidity and mortality of reuse [41, 42]. Apart from
dialysis payment of $51,229, which also includes hospitalthe medical validity of the reuse practice, the dialyzer
admission fees (estimated from NMCE · SMCA-PHIreuse practice has several obstacles in Japan.
data, 1992) [4, 32, 49].As the Japanese medical payment system is based on
As for the outcome of this “cheap” dialysis, in additionthe principle of fee-for-service [although there is some
to the frequent hospital admissions, the United States hastendency toward the diagnosis-related group (DRG)
the highest one-year crude death rate recorded among allpayment system such as one seen in the comprehensive
of the industrialized countries every year [50].fee shown in Tables 3 and 4], the dialyzer cost is paid in
Caution must be used in the country-to-country com-addition to the technical fee.
parisons of medical outcome and medical economy, inAs a result, the care providers are reluctant to reuse
light of the obvious differences in the patients’ features,dialyzers, as they cannot receive a financial benefit from
including transplantation rates, diabetic population, ra-the margin between the fixed rate from the point fee
cial disparity for the death rates [51], and the differencessystem and the market price by refusing it. In 1998, this
in the definition and payment system of the cost [52].margin was estimated to be 17.5%.
Nevertheless, the author hopes that the Japanese policyAlso, in 1987, the Diet has passed “The Clinical Engi-
makers learn from the U.S. Medicare’s outcome whenneer Act” to improve the competency level of the medi-
planning for a reduction in the ESRD expenditure incal technicians involved in dialysis, extracorporeal circu-
the future.lation, and artificial respiration [43]. Those who are the
candidates for the registered CE must pass a national
Maintenance of a quality-based payment systemexamination after graduating from either a three-year
for dialysisprofessional school or a four-year university (science and
Although a further reduction of the ESRD expendi-engineering schools).
ture is mandatory, caution must be paid in curtailing theThese CEs can operate life-sustaining apparatuses, in-
cluding dialysis machines and dialyzers, and their wages reimbursement for dialysis therapy. We must carefully
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The economic cost of ESRD and Medicare spending for alternativeevaluate the impact on expeditious reduction in the di-
modalities of treatment. Am J Kidney Dis 32(Suppl 1):S118–S131,
rect cost for dialysis. 1998
From the overall cost-saving viewpoint, it is not feasi- 17. US Renal Data System: USRDS 1998 Annual Data Report. XII.
International comparisons of ESRD therapy. Am J Kidney Disble to drastically curtail the direct dialysis fee further.
32(Suppl 1):S136–S141, 1998Should the dialysis comprehensive fee be reduced, an 18. US Renal Data System: USRDS 1999 Annual Data Report. IV.
incentive must be given to maintain the dialysis quality, Patient characteristics at the start of ESRD: Data from the HCFA
Medical Evidence Form. Am J Kidney Dis 34(Suppl 1):S63–S73,for example, by paying more for longer session dialysis
1999[53] and less for facilities where qualified dialysis person- 19. Burton B, Day LM, Pierpoint KL, Vlcheck DL: Can a global
nel, for example, nurses and CEs, are understaffed [54]. payment system work for the ESRD program? Nephrol News Is-
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